Ziopharm Oncology Appoints Kevin Buchi to its Board of Directors
Life Sciences industry veteran; 15-year Cephalon executive, serving progressively
as CFO, COO and then CEO at time of $6.8 billion acquisition by Teva
Doug Pagán Steps Down from Board of Directors
Boston, September 22, 2020 Ziopharm Oncology, Inc. (Ziopharm or the Company) (Nasdaq:ZIOP),
today announced the appointment of J. Kevin Buchi to the Companys Board of Directors and as Chair of the Boards Audit Committee. Additionally, Ziopharm announced that, in response to the results from the Companys recent annual
meeting of stockholders, Doug Pagán has resigned from the Board.
Mr. Buchi has deep life sciences industry experience, notably 15 years with
Cephalon, including serving as its Chief Executive Officer during Cephalons acquisition by Teva Pharmaceuticals in 2011 for $6.8 billion. Subsequently, Mr. Buchi served as Chief Executive Officer of TertraLogic Pharmaceuticals, and
more recently as Chief Executive Officer of Biospecifics Technologies, prior to his retirement.
We are delighted to welcome Kevin to our Board of
Directors, said Scott Tarriff, Chairman of the Ziopharm Board of Directors. Kevin is an accomplished executive and director, whose extensive industry experience and business and financial acumen will complement the Board. We also wish to
thank Doug for his many contributions since joining the Ziopharm Board in 2018, a critical time in the Companys history, while we exited a corporate partnership and established the foundation for our core programs today. Over the past year, we
have added four strong directors to our Board, including James Huang in July and Dr. Chris Bowden and Heidi Hagen last year. Looking ahead, we expect our Board will continue to evolve to reflect the needs of our business as we evolve into a
Mr. Buchi added, This is an exciting time for Ziopharm, as the Company has established a broad portfolio of
innovative clinical programs to treat solid tumors and a talented team to drive company-sponsored trials in all three core programs. I am delighted to begin collaborating with Laurence and his team, as well as the other members of Ziopharms
Board of Directors.
Following the acquisition of Cephalon by Teva in 2011, Mr. Buchi served as corporate vice president of global branded
products at Teva. Following Teva, he was CEO TetraLogic Pharmaceuticals and Biospecifics Technologies. In addition, Mr. Buchi currently serves as chairman of Dicerna Pharmaceuticals, and as a director of Amneal Pharmaceuticals and Benitec
Biopharma Ltd. Mr. Buchi earned a B.A. in Chemistry from Cornell University and a Masters in Management, Accounting and Finance from the Kellogg School of Management at Northwestern University.
The Companys Board consists of eight Directors, including seven non-executive Directors. The Board will continue
to actively review the Board membership to ensure the skills and experience of Directors support the progress and future prospects of the business.
About Ziopharm Oncology, Inc.
Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the bodys immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach,
Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor. Ziopharms